Abstract

This research proposal is designed to enable continued participation in the Primary Breast Cancer Therapy Group -- NSABP. The overall specific aims of the NSABP are to improve disease-free survival and survival in patients with primary operable breast and colorectal cancers. (See the NSABP Headquarters grant application for protocol rationale and overall scientific achievements to date) The Hotel-Dieu of Montreal has been an NSABP Member since July 1981 and is currently following 314 patients on long term adjuvant protocols. We expect to increase patients accrual to 75 per year. The entry of these patients into NSABP protocols will enable a more rapid and effective evaluation of current therapeutic regimens and will provide information for the design of future studies. The Hotel-Dieu of Montreal has been the second highest accrual in NSABP B-18 with 70 patients. Protocol B-18 is a high priority protocol of the NCI. Our breast ranking was 1st among 20 Grants with a perfect score of 100% in the NSABP evaluation score as of 12/31/90.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA044066-08
Application #
2091369
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1987-04-15
Project End
1997-01-31
Budget Start
1994-02-01
Budget End
1995-01-31
Support Year
8
Fiscal Year
1994
Total Cost
Indirect Cost

  Institution

Name
Hotel Dieu de Montreal
Department
Type
DUNS #
City
Montreal
State
PQ
Country
Canada
Zip Code

  Publications

Bear, Harry D; Tang, Gong; Rastogi, Priya et al. (2017) The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40. Ann Surg Oncol 24:1853-1860
Jatoi, Ismail; Bandos, Hanna; Jeong, Jong-Hyeon et al. (2016) Time-Varying Effects of Breast Cancer Adjuvant Systemic Therapy. J Natl Cancer Inst 108:
Wickerham, D Lawrence; Vogel, Victor G (2015) Breast cancer chemoprevention: the saga of underuse continues. J Natl Cancer Inst 107:399
Bear, Harry D; Tang, Gong; Rastogi, Priya et al. (2015) Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol 16:1037-1048
Swain, Sandra M; Tang, Gong; Geyer Jr, Charles E et al. (2013) Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. J Clin Oncol 31:3197-204
Paterson, Alexander H G; Anderson, Stewart J; Lembersky, Barry C et al. (2012) Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol 13:734-42
Bear, Harry D; Tang, Gong; Rastogi, Priya et al. (2012) Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 366:310-20
Krag, David N; Anderson, Stewart J; Julian, Thomas B et al. (2010) Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11:927-33